病理性近视眼继发脉络膜新生血管治疗策略的研究进展  

Research progress of treatment strategies for choroidal neovascularization secondary to pathological myopia

作　　者：史绪晗 魏文斌 Shi Xuhan;Wei Wenbin(Beijing Tongren Eye Center,Beijing Tongren Hospital,Capital Medical University,Beijing Key Laboratory of Ophthalmology&Visual Sciences,Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment,Beijing 100730,China)

机构地区：[1]首都医科大学附属北京同仁医院北京同仁眼科中心北京市眼科学与视觉科学重点实验室北京市眼内肿瘤诊治研究重点实验室,100730

出　　处：《中华眼科杂志》2019年第10期791-795,共5页Chinese Journal of Ophthalmology

基　　金：中国科学院战略性科技先导专项项目(XDA01030000);国家自然科学基金(81570891);北京市医院管理局"登峰"人才培养计划(DFL20150201);眼内肿瘤诊治研究北京市重点实验室2015年度科技创新基地培育与发展专项项目(Z151100001615052);北京市医院管理局临床医学发展专项经费资助(扬帆计划)(ZYLX201307)。

摘　　要：病理性近视眼指高度近视眼伴眼底病理性改变,继发脉络膜新生血管是其严重并发症之一,也是导致视力下降的主要因素。目前一线治疗方法是抗血管内皮生长因子(VEGF)治疗,具有疗效确定、安全性高、视力预后较好等优势。常用抗VEGF药物包括贝伐单克隆抗体、雷珠单克隆抗体、阿柏西普、康柏西普。主要治疗方案包括1+pro re nata(PRN)和3+PRN,临床多以雷珠单克隆抗体治疗病理性近视眼继发脉络膜新生血管的Ⅱ期临床试验提出的标准对再注射进行评估。本文针对抗VEGF治疗的优势、药物选择、治疗方案及再注射标准,对相关研究进展进行综述,以期为临床治疗提供参考。Pathological myopia refers to high myopia with fundus pathological changes.Choroidal neovascularization is one of its serious complications,and also the main cause of visual loss.Currently,the first-line treatment is anti-VEGF treatment,with good efficacy,high safety,good prognosis,and other advantages of vision.Commonly used anti-VEGF drugs include bevacizumab,ranibizumab,aflibercept,and conbercept.The main treatment strategies include 1+pro re nata and 3+pro re nata,and the standard of REPAIR test is often used to evaluate the re-injection.This article reviews the advantages of anti-VEGF therapy,drug selection,treatment strategy,and re-injection criteria.(Chin J Ophthalmol,2019,55:791-795)

关 键 词：近视 退行性 脉络膜新生血管化 血管内皮生长因子A 血管生成抑制剂 

分 类 号：R73[医药卫生—肿瘤]